AMRS - Amyris, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.1300
+0.1700 (+4.29%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.9600
Open4.0000
Bid3.9000 x 1300
Ask4.1900 x 900
Day's Range3.9700 - 4.1800
52 Week Range1.8700 - 9.2900
Volume379,303
Avg. Volume2,857,096
Market Cap405.12M
Beta (3Y Monthly)1.73
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Will Amyris Wisely Return Its Focus to Consumer Brands?
    Motley Fool18 days ago

    Will Amyris Wisely Return Its Focus to Consumer Brands?

    An overlooked announcement provides an opportunity for a management team that has lost the trust of investors.

  • Temasek Holdings’ Latest Moves
    Insider Monkey22 days ago

    Temasek Holdings’ Latest Moves

    Temasek Holdings is a Singapore-based global investment company with a long-term-focused investment horizon. It was founded back 1974, and since then it has achieved compounded annualized return of 15% in Singapore dollar terms. Even though it is based in Singapore, it offers 11 offices around the world. Temasek Holdings look for the investment opportunities in […]

  • Can Amyris Succeed With Its Latest Turnaround?
    Motley Fool28 days ago

    Can Amyris Succeed With Its Latest Turnaround?

    The company hopes new products in development and a reshuffled debt portfolio can deliver long-awaited growth and profits. Investors have heard that before.

  • Amyris (AMRS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
    Zackslast month

    Amyris (AMRS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

    Amyris (AMRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Insiders Roundup: Facebook, Amyris
    GuruFocus.com2 months ago

    Insiders Roundup: Facebook, Amyris

    Largest insider trades of the week

  • Here's Why Amyris Is Soaring Today
    Motley Fool2 months ago

    Here's Why Amyris Is Soaring Today

    Another day, another transaction. Is the synthetic biology pioneer better positioned to execute now?

  • Here's Why Amyris Jumped as Much as 28.9% Today
    Motley Fool2 months ago

    Here's Why Amyris Jumped as Much as 28.9% Today

    The business received a small lifeline from one of its largest shareholders.

  • MarketWatch2 months ago

    Amyris stock plunges 24% after accounting errors disclosed

    Amyris Inc. said late Thursday that due to accounting errors the company will have to restate several quarterly and annual reports. Amyris stock plunged 24% in after-hours trading. Amyris said that as a result of the errors it will cut fiscal 2018 revenue by $12 million to $16 million and net income by $7 million to $11 million. The errors were the result of the way the company handled revenue from royalty payments, the company said. Amyris stock is down 13.5% this year, as the S&P 500 index has gained 15%.

  • Why Amyris Stock Fell 30.9% Today
    Motley Fool2 months ago

    Why Amyris Stock Fell 30.9% Today

    Shares of the synthetic biology pioneer have risen and fallen by double digits many days in recent weeks.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of AMRS earnings conference call or presentation 18-Mar-19 8:30pm GMT

    Q4 2018 Amyris Inc Earnings Call

  • How AT&T Stock Has Performed Recently
    Market Realist3 months ago

    How AT&T Stock Has Performed Recently

    Viacom Finally Renews Contract with AT&T(Continued from Prior Part)AT&T’s stock price movementAT&T (T) stock rose 0.03% on March 22. The stock has fallen 0.2% in March, while it has risen 10.7% in the year-to-date period. The market

  • 3 Takeaways From Amyris' Q4 2018 Earnings Report
    Motley Fool3 months ago

    3 Takeaways From Amyris' Q4 2018 Earnings Report

    The company reported poor operating performance in 2018, but has attempted to focus the attention of investors on its future.

  • Here's Why Amyris Collapsed Today
    Motley Fool3 months ago

    Here's Why Amyris Collapsed Today

    The company notified the Securities and Exchange Commission that it couldn't file its annual report on time. It gave three reasons.

  • Benzinga3 months ago

    Amyris Signs $300M Deal For Fermentation-Derived CBD Products

    Amyris, which produces ingredients in the health and wellness, clean beauty and flavors and fragrances markets, said it has clinched a deal with newly formed LAVVAN Inc., which is working on bringing the first fermentation-derived cannabinoid products to market. The announcement comes after a previously announced term sheet and includes further milestone payments related to additional targeted products. Amyris, with its expertise in terpenes, said it will leverage its automated processes and R&D staff in the development of cannabinoid pathways.

  • Amyris Inc (AMRS) Q4 2018 Earnings Conference Call Transcript
    Motley Fool3 months ago

    Amyris Inc (AMRS) Q4 2018 Earnings Conference Call Transcript

    AMRS earnings call for the period ending December 31, 2018.

  • Analysts Estimate Amyris (AMRS) to Report a Decline in Earnings: What to Look Out for
    Zacks3 months ago

    Analysts Estimate Amyris (AMRS) to Report a Decline in Earnings: What to Look Out for

    Amyris (AMRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Did You Manage To Avoid Amyris’s (NASDAQ:AMRS) Devastating 93% Share Price Drop?
    Simply Wall St.3 months ago

    Did You Manage To Avoid Amyris’s (NASDAQ:AMRS) Devastating 93% Share Price Drop?

    Some stocks are best avoided. We don't wish catastrophic capital loss on anyone. Anyone who held Amyris, Inc. (NASDAQ:AMRS) for five years would be nursing their metaphorical wounds since theRead More...

  • A Massive Disruption Could Be on the Way for Marijuana: 3 Stocks Poised to Profit
    Motley Fool3 months ago

    A Massive Disruption Could Be on the Way for Marijuana: 3 Stocks Poised to Profit

    Cannabinoids that don't require cannabis just might make these stocks huge winners in the future.

  • Will Cannabis Producers Ditch Greenhouses for Bioreactors?
    Motley Fool4 months ago

    Will Cannabis Producers Ditch Greenhouses for Bioreactors?

    Plants aren't always the perfect medium for producing high-value compounds. Turns out, cannabinoids can be brewed with microbes instead.

  • InvestorPlace4 months ago

    Amyris Stock Can Run Much Higher Than You Think

    Investors can now consider renewable products company Amyris (NASDAQ:AMRS) as a "marijuana stock." The Emeryville, California-based firm signed a deal to license cannabinoid products. This sent AMRS stock surging much higher in Tuesday trading.Now, investors must decide if and how to trade Amyris stock. Given the renewed popularity of marijuana stocks, the stock will likely remain a momentum stock for the foreseeable future. New Deal Changes the Perception of AMRS StockAMRS stock rose by more than 73% on Tuesday upon announcing its entrance in the cannabinoid market. The company did not reveal the name of its partner in this agreement; however, we know the value of the deal will come to $255 million. Some of this could come in the form of royalty payments as Amyris works to bring sustainably sourced CBD to the beverage and skin care markets. The final agreement should happen by the end of March. Products from this deal should appear on shelves 18 to 24 months after final approval.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBefore this agreement, Amyris survived as a little-known industrial biotech company that launched its IPO in 2010. Since peaking in 2011, the stock has lost about 99% of its value. Now, thanks to cannabis, it could be on its way to a long-awaited comeback. The Deal Will Bolster Robust Revenue GrowthWhile the association with weed will likely boost AMRS stock, its financials have shown improvement for some time. In the middle of the decade, stagnant revenue and massive losses seem to define AMRS. * 7 Recession-Proof Stocks to Buy as the Boom Ends However, the company more than doubled revenues in 2016 and again in 2017. Although this growth has slowed, analysts had predicted revenue increases would remain well into the double digits before this announcement. Losses have also narrowed in recent years. With cannabis-related sales coming in, both revenue and earnings should improve dramatically.Also, even after its massive upward surge, AMRS trades at just over two times sales. This compares well to cannabis industry giants such as Canopy Growth (NYSE:CGC) and Tilray (NASDAQ:TLRY), both of which maintain triple-digit price-to-sales ratios.Furthermore, Canopy's market cap of nearly $16 billion is more than 40 times the size of Amyris's $390 million market cap. Yet with 2018 revenues of only C$255 million ($193.4 million), Canopy will only bring in about 20% more in revenue than the $161.8 million analysts expect from Amyris. While I do not think AMRS will catch up to Canopy's market cap, I think this deal will help close much of that gap. AMRS Could Benefit From an American Cannabis BoomMoreover, marijuana stock investors remember the Canadian cannabis boom that cooled off following full legalization. Now, with hemp achieving legal status in the U.S., a comparable American cannabis boom looks to have just begun. Canopy, who will begin producing hemp in New York, again trades at levels not seen since legal status became official in Canada. * 10 F-Rated Stocks That Could Break Your Portfolio If such a boom has in fact started in the U.S., this should bode well for AMRS stock regardless of fundamentals. Given the 73% surge in one day, the stock will more likely pull back for now. However, over time, the boom in cannabis stocks should take it higher. This separation from fundamentals will turn off some buyers. However, for those comfortable trading mostly on momentum, I see the potential for profit in Amyris stock. Final Thoughts on Amyris StockThe move into the cannabis sector will boost Amyris stock in the near term regardless of earnings. Amyris has spent years as a little-known biotech company whose stock had gained little traction in recent years. However, a move into the marijuana sector sent AMRS more than 70% higher in just one day.This occurs as a U.S. cannabis boom has likely ignited thanks to hemp's new legal status. Despite losses, AMRS stock looks cheap in comparison to marijuana giants such as Canopy Growth. If nothing else, the momentum should take the company's price-to-sales ratio much higher.Like other marijuana stocks, AMRS should grow well beyond its fundamentals. This will mean any movement or purchase decisions will drive on momentum shifts. This goes beyond the comfort level of some investors. However, for those willing to take that risk, AMRS appears poised to bring higher returns to those with a high tolerance for risk.As of this writing, Will Healy did not hold a position in any of the aforementioned securities. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks That Won Super Bowl Sunday * 7 High-Yield ETFs for Brave Investors * 10 F-Rated Stocks That Could Break Your Portfolio Compare Brokers The post Amyris Stock Can Run Much Higher Than You Think appeared first on InvestorPlace.

  • What Is Amyris (AMRS), And Why Is Its Stock Soaring?
    Zacks4 months ago

    What Is Amyris (AMRS), And Why Is Its Stock Soaring?

    Shares of bioscience firm Amyris (AMRS) skyrocketed more than 70% on Tuesday after the company announced a collaboration deal focused on developing, licensing, and commercializing cannabinoid products.

  • Option Bulls Flock to Penny Stock After Weed Deal
    Schaeffer's Investment Research4 months ago

    Option Bulls Flock to Penny Stock After Weed Deal

    Amyris disclosed a cannabinoid partnership

  • Amyris News: AMRS Stock Explodes on Cannabinoid Deal
    InvestorPlace4 months ago

    Amyris News: AMRS Stock Explodes on Cannabinoid Deal

    There's a new bit of Amyris news that has AMRS stock flying high on Tuesday. Source: Shutterstock Amyris (NASDAQ:AMRS) has announced that it has signed a deal for partnership development, licensing and commercialization of cannabinoid products. The company isn't currently revealing the other party in the deal. What the Amyris news does reveal is that this partnership is worth $255 million. This includes one upfront payment to the company, as well as several others over the next 12 months to 36 months. InvestorPlace - Stock Market News, Stock Advice & Trading Tips AMRS is also eligible to receive royalty payments in connection to the cannabinoid products. The company says that it is expecting this to result in significant royalty payments due to the size of the cannabinoid market. "We are pleased to have been recognized by a well-capitalized partner as the company best suited to leverage fermentation-based technology in the production of the best quality and lowest cost and sustainably-produced cannabinoids," John Melo, President and CEO of AMyris, said in a statement. "We share the mission of our partners to become the leader in sustainably-sourced CBD products in the near term as we focus on enabling the global beverage and skin care markets, including our own brands, to support the health and wellness of people and our planet." * 7 Stocks That Won Super Bowl Sunday Amyris says that it and its partner are expecting to sign off on a final agreement by the end of March. It will begin development right after this and expects to have products ready for the market in the following 18 months to 24 months. AMRS stock was up 41% as of noon Tuesday. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 F-Rated Stocks That Could Break Your Portfolio * 5 Fintech Stocks to Buy As This Mega Trend Gains Steam * 10 Cold Weather Stocks to Heat Up Your Returns As of this writing, William White did not hold a position in any of the aforementioned securities. Compare Brokers The post Amyris News: AMRS Stock Explodes on Cannabinoid Deal appeared first on InvestorPlace.